Elfriede holds VVUS 1.71: Vivus stock has been stuck ever since the initial excitement wore off.

The sensible solution for current bond holders was to clean up the books by covering the short and assessing the Icahn offer in the subsequent days. The Icahn announcement likely gave incentive to make that highly profitable transaction anyway. On one hand, covering a short position entered at about $15 at about $1.50 is a big win. It appears that the volume in the next two trading days was enough for all of those holders to cover their short position on the open market. It is essentially standard operating procedure.


Tequila:
Both of these companies are attempting to make a generic Qsymia and are in litigation with Vivus.

Corie:
In my opinion a great play would be for Icahn to become involved in the equity and sell Qsymia off to either Actavis (ACT) or Teva.

Athena:
If Icahn's goal is to do something with Qsymia, he needs to consider the debt instrument that carries the Qsymia rights in terms of collateral.

Stephine:
This is important for investors to understand, because it carries a direct impact on what Icahn can possibly be interested in.

Chasity:
Digging deeper into other dynamics may give some hints as to what Icahn's intent may be.

Helen:
It also has a side that could be very shareholder friendly.

Malka:
That leverage has a side to it that is not shareholder friendly in the slightest.

Ashanti:
It gives Icahn a different type of leverage.

Lee:
This is an aggressive move that the company has no say in.

Tien:
Icahn's Vivus move is buying up debt at a steep discount.

Vivus (NASDAQ:VVUS)
//stockhand.net/us/?q=nasdaq%3Avvus&id=585324